Muthu Vaduganathan

Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA therapies: ✅ Empagliflozin (#EMPEROR) ✅ Dapagliflozin (#DELIVER) ✅ Sotagliflozin (#SOLOISTWHF) ✅ Sacubitril/Valsartan (#PARAGONHF) ✅ Finerenone (#FINEARTSHF)

Combining SGLT2i & MRAs in Heart Failure and CKD: Playing the Long Game @JACCJournals Our thoughts in light of recent trials of simultaneous initiation of both agents in HFpEF (SOGALDI-PEF) & CKD (CONFIDENCE): jacc.org/doi/10.1016/j.…

#HFimpEF is common, but data are limited on #GDMT & outcomes. In @JACCJournals, the largest look at HFimpEF in US to date. 🎯>28K new HFrEF pts, 1 in 3 improved to HFimpEF. 🎯 GDMT ⤵️ after HFimpEF. 🎯 Many pts remained at ⏫ risk. 💡 Tailored trials & #ImpSci strategies needed.

In a few weeks, cardiology professionals will gather at #ESCCongress 2025 with #WCCardio for an unforgettable experience. Enjoy networking opportunities, celebrations, entertainment, CV health checks, & so much more. See what’s waiting in Madrid & register by 31 July to save…

We are excited to work with @StanfordDeptMed, @SmidtHeart, @mghliver, and @KPDOR with the support of @American_Heart to refine and prospectively evaluate AI opportunistic screening approaches for Cardiovascular-Kidney-Metabolic Health! Chronic Liver and Kidney Disease is common…

#heartfailure improved EF ⬆️Rising prevalence 🚨Despite partial recovery, risk for MACE remains 🚦Clinical gaps and therapeutic approaches under investigation Definitions, epidemiology and more ➡️ doi.org/10.1016/j.jacc… @JACCJournals @MarcoMetra @mvaduganathan @GianluSava

RESEARCH | @clarissamliu, @DanielJDrucker, M Véniant et al (@Amgen, @SinaiHealth) Part 1: This study and a co-pub delve into how both GIP receptor agonists and antagonists trigger weight loss through different mechanisms. nature.com/articles/s4225…

Tomorrow is a big day for @JCFINT… Thank you to the 100+ author groups who have chosen to share their science and perspectives with us over the last 6 months The privilege of bringing this work to you starts tomorrow! @JasonKatzMD @ElliottMillerMD @JulieDoberne @SarahChuzi

Out now — an analysis led by our #HFC members, the first to evaluate the inclusion of social determinants of health (SDOH) in clinical trials and to propose a lean approach to SDOH incorporation into trial data. @EMDeFilippisMD sciencedirect.com/science/articl…

Finerenone was effective in heart failure patients with mildly reduced or preserved ejection fraction, regardless of atrial fibrillation (AF) status, and new-onset AF was linked to higher risk of adverse outcomes. ja.ma/44IgNOA @HFpEF @AdriaanVoors @mvaduganathan

That’s a wrap! What an amazing weekend in Charleston for the HFpEF conference. Can’t wait for next year. Phenomenal talks and tons of learning plus being in an awesome location doesn’t hurt. @RyanTedfordMD @robmentz @JeffTeuteberg @JennaSkowronski @noshreza @mvaduganathan

3 in 4 adults with #CKM overlap have uncontrolled risk factors. And it’s getting worse. NHANES data sends a clear warning 🚨📉 jacc.org/doi/10.1016/j.… #JACC #CKD #CVD #T2D @mvaduganathan

Dr. Muthu Vaduganathan from @harvardmed brought MRAs back into the spotlight at the #CharlestonHFpEF Conference, highlighting the FINEARTS trial—because when it comes to HFpEF, mineralocorticoid blockade is looking like a fine art indeed. More data coming! 🎨🫀 #HFpEF…

@LitwinSheldon just kicked off the #CharlestonHFpEFConference 2025 with style—southern charm meets cutting-edge science. Let the heart failure fireworks begin and beware of the HFpEF Sharks! 🎇🫀 #HFpEF @VishalNRao @Carnicelli_Ant @VerwerftJan @GLewisCardiol @TomCascinoMD…

A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial In this nationwide pragmatic, 2x2 factorial implementation trial, electronic…

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction The FINEARTS-HF Randomized Clinical Trial Among patients with HFmrEF/HFpEF in the FINEARTS-HF randomized clinical trial, higher proportions of cardiovascular and overall mortality in…

“CV Prevention is in reach but only w/ implementation that’s global, upstream, and grounded in data.” In this week’s #JACCThisWeek, I highlight Focus Issue on Prevention: polypills, syndemics, PREVENT, inclisiran, and more. @jaccjournals 🎧 Listen here: jacc.org/digital-conten…

Dr. @ankeetbhatt offers perspective on implementation science, “the scientific study of methods and strategies that facilitate the uptake of evidence-based practice and research into regular use by practitioners and policymakers." bit.ly/3oGbHeU #TransformCVCare

In heart failure patients with mildly reduced or preserved ejection fraction, cardiovascular and sudden deaths were higher in those with EF <50%. Finerenone did not significantly reduce cause-specific mortality. ja.ma/4nC6sw2 @mvaduganathan @HFpEF @AdriaanVoors

New episode this week! We discuss pragmatic trial infrastructure in Denmark, implementation science in nephrology and how new approaches to recruitment can improve access, equity and representation in trials #kidneycompass